Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
09 oct. 2024 08h00 HE
|
Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
03 oct. 2024 08h00 HE
|
Evaxion Biotech
Improved precision of the AI-Immunology™ platform in predicting clinically relevant vaccine targets boosts the potential of its AI-derived vaccine candidates The improvement has been achieved through...
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
14 août 2024 07h00 HE
|
Achilles Therapeutics PLC
– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa...
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
22 mai 2024 07h00 HE
|
Achilles Therapeutics PLC
Research collaboration combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform
Promising Personalized Approach to Liver Cancer Therapy Made Possible by DNA-based Neoantigen Research Designed at The Wistar Institute
30 avr. 2024 10h18 HE
|
The Wistar Institute
PHILADELPHIA, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Hepatocellular carcinoma (HCC), or liver cancer, is an aggressive malignancy with limited treatment options. An immunologically cold cancer —...
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
01 avr. 2024 16h01 HE
|
Gritstone bio
-- Early progression-free survival (PFS) trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population ([95% CI, 0.34-1.67]; 62% censored) and 0.52 (48% relative risk reduction...
CAR-T Funding Report 2024: Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions
18 mars 2024 04h52 HE
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024" report has been added to ...
Global Intratumoral Cancer Therapies Market Report 2023: Increasing Incidence of Cancer is Expected to Propel Growth
16 juin 2023 05h08 HE
|
Research and Markets
Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Intratumoral Cancer Therapies Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides...
mRNA Cancer Therapies Patent Landscape 2022: Featuring BioNTech, Moderna, Novartis, Sanofi & Others
04 oct. 2022 04h03 HE
|
Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering. For nearly three decades, extensive efforts...
Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 janv. 2022 07h00 HE
|
Gritstone bio
-- Phase 2/3 GRANITE-CRC-1L trial has registrational intent -- -- Updated data from Phase 1/2 trial in end-stage metastatic MSS-CRC further support the association of circulating tumor DNA (ctDNA)...